Peficitinib

• CAT Number: I005617
• CAS Number: 944118-01-8
• Molecular Formula: C18H22N4O2
• Molecular Weight: 326.41
• Purity: ≥95%
• Synonyms: ASP015K
• Target: Stem Cell/Wnt
• Solubility: DMSO: ≥ 60 mg/mL
• Storage: Store at -20°C
• IC50: 3.9/5.0/0.71 nM (for JAK1/2/3) , 4.8 nM (for Tyk2)
• IUPAC Name: 4-[[(1R,3S)-5-hydroxy-2-adamantyl]amino]-1H-pyrrolo[2,3-b]pyridine-5-carboxamide
• InChI: InChI=1S/C18H22N4O2/c19-16(23)13-8-21-17-12(1-2-20-17)15(13)22-14-10-3-9-4-11(14)7-18(24,5-9)6-10/h1-2,8-11,14,24H,3-7H2,(H2,19,23)(H2,20,21,22)/t9-,10-,11+,14+,18-
• InChIKey: DREIJXJRTLTGJC-ZKVNVPQCSA-N
• SMILES: NC(C1=CN=C2C(C=CN2)=C1N[C@@H]3[C@H](C4)C[C@@]5(O)C[C@@H]3C[C@@H]4C5)=O

Peficitinib(CAT: I005617) is a potent and selective Janus kinase (JAK) inhibitor widely utilized in immunology and inflammation research. By targeting JAK1, JAK2, JAK3, and TYK2, it disrupts cytokine-mediated signaling pathways, making it a valuable tool for studying autoimmune and inflammatory diseases. Researchers leverage Peficitinib to explore therapeutic approaches for conditions such as rheumatoid arthritis, psoriasis, and other immune-related disorders. With its high specificity and efficacy, Peficitinib is essential for preclinical studies aiming to advance drug discovery and develop innovative treatments for chronic inflammatory diseases.